© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Sheela Tejwani, MD, reviews the case of an 83-year-old man with biochemically recurrent mCSPC and discusses the possible treatment approaches.
October 13th 2022
Sheela Tejwani, MD, presents the case of an 83-year-old man with mCSPC, and shares her first impressions as compared to her typical patients.
Dr Tejwani lists the frontline treatment options currently available for mCSPC and reviews the chosen treatment regimen in the presented patient case.
An expert oncologist describes her approaches to treating patients with castration-sensitive prostate cancer and low-volume metastatic disease.
Sheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.